Antipodes Partners LTD Ultragenyx Pharmaceutical Inc. Transaction History
Antipodes Partners LTD
- $3.16 Billion
- Q1 2025
A detailed history of Antipodes Partners LTD transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 1,568 shares of RARE stock, worth $55,914. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,568Holding current value
$55,914% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
336Shares Held
88.9MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$356 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$200 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$148 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$115 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$93.4 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.5B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...